Loading viewer...
investor_presentation
Format: PDF investor_presentation
Quanterix investor presentation dated November 2022.
November 8, 2022Q3 2022 Earnings Call 2Forward- Looking Statements & Pro- Forma Financial Measures
This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other w ords or
expressions referencing future events, conditions or circumstances) are intended to identify forward -looking statements. Forward -
looking statements in this presentation are based on Quanterix’ expectations and assumptions as of the date of this presentat ion.
Each of these forward- looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ
from those expressed or implied in the forward -looking statements in this presentation are discussed in Quanterix’ filings with the U.S.
Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quant erix
assumes no obligation to update any forward -looking statements contained herein to reflect any change in expectations, even as new
information becomes available.
To supplement the Company’s financial statements presented on a GAAP basis, the Company has provided certain pro-
forma financial measures. Management uses these pro- forma measures to evaluate the Company’s operating performance in a
manner that allows for meaningful period -to-period comparison and analysis of trends in its business. Management believes that such
measures are important in comparing current results with other period results and are useful to investors and financial analysts in
assessing the Company’s operating performance. The pro- forma financial information presented here should be considered in
conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encour aged
to review the reconciliation of these pro- forma measures to their most directly comparable GAAP financial measures set forth herein
and in the earnings press release issued earlier today.Q3 2022 Q4 2022 H1 2023 H2 2023
completed in July, business realignment and restructure in August
team and charter established
products phase 1 Stability and variance improve
ments for common assay
Identify primary wave of improvements transitioned into manufacturing Manufacturing implementation of primary wave
Raw material specifications, stability and qualification
Automated WIs & DocumentationProcess automation
Product and process harmonization
Pro-forma Gross Margin* 28.3% 35.0%
CEO transition on April 25th
Business strategic review, starting in JuneProgress on Assay Redevelopment Roadmap
Revenue $23.5M $26.6M $24M -$26M
Preview truncated — download the full document for the complete content.
investor_presentation
24 Pages
investor_presentation
27 Pages
Triumph Group
investor_presentation
VA Tech Wabag